Colleen Moretti | Authors


Pralsentinib Demonstrates Tolerability and Elicits Durable Responses in RET Fusion-Positive NSCLC

June 04, 2021

In the phase 1/2 ARROW study, pralsentinib was found to be well-tolerated and showed durable responses as treatment of patients with RET fusion-positive non-small cell lung cancer, including those who were not eligible for platinum-based therapy.